Consideraciones prácticas acerca de la detección del sesgo de publicación

Pérez, Silvia Palma; Rodríguez, Miguel Delgado

doi:10.1157/13101085

Cited by 56 publications

(20 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Nevertheless, the limitations of this work include the number of articles included, which restricts interpretation using the methods of Egger and Begg, despite the fact that no publication bias of statistical significance were found 67 . It should not be forgotten, either that all the publications considered were written in English, and the tendency in the academic world is to publish the most striking results in international journals whereas local journals and grey literature report not so impactful findings.…”

Section: Discussionmentioning

confidence: 95%

The role of EZH2 in overall survival of colorectal cancer: a meta-analysis

Vilorio-Marqués

Martín

Diez-Tascón³

et al. 2017

Sci Rep

View full text Add to dashboard Cite

Enhancer of zeste homolog 2 (EZH2) is the catalitic subunit of polycomb repressive complex 2 and mediates gene silencing. EZH2 is overexpressed in many cancers and correlates with poor prognosis. The role of the gene EZH2 in colorectal cancer survival is uncertainly, the aim of this study is clear this relationship. Relevant literaure was searched from electronic databases. A meta-analysis was performed with elegible studies which quantitatively evaluated the relationship between EZH2 overexpression and survival of patients with colorectal cancer. Survival data were aggregated and quantitatively analyzed. We performed a meta-analysis of 8 studies (n = 1059 patients) that evaluated the correlation between EZH2 overexpression and survival in patients with colorectal cancer. Combined hazard ratios suggested that EZH2 overexpression was associated with better prognosis of overall survival (OS) HR(hazard ratio) = 0.61 95% CI (0.38–0.84) We performed bias analysis according Egger and Begg,s test and we did not find publication bias. EZH2 overexpression indicates a better prognosis for colorectal cancer.

show abstract

Section: Discussionmentioning

confidence: 95%

The role of EZH2 in overall survival of colorectal cancer: a meta-analysis

Vilorio-Marqués

Martín

Diez-Tascón³

et al. 2017

Sci Rep

View full text Add to dashboard Cite

show abstract

“…If I 2 statistic was ≤ 50%, we considered these studies as heterogeneous, and if they were = 50%, then we judged them to be homogeneous ( 24 ). To detect the publication bias, we drew a funnel plot for a single outcome with more than 10 eligible studies ( 25 , 26 ). For studies with multiple-arm design, essential data were extracted based on methods recommended by the Cochrane Collaboration ( 15 ).…”

Section: Methodsmentioning

confidence: 99%

Oral Zinc Sulfate for Prevention and Treatment of Chemotherapy-Induced Oral Mucositis: A Meta-Analysis of Five Randomized Controlled Trials

Tian

Liu

et al. 2018

Front. Oncol.

View full text Add to dashboard Cite

Chemotherapy-induced oral mucositis is an extremely serious complication faced by cancer patients. The role of oral zinc sulfate in preventing and treating chemotherapy-induced oral mucositis remains a subject of debate. The aim of this systematic review is to assess the potential of oral zinc sulfate to alleviate this morbid condition. A systematic search was conducted electronically in PubMed, EMBASE, and the Cochrane Central Register of Controlled Trials (CENTRAL) to capture all potential randomized controlled trials investigating efficacy and safety of oral zinc sulfate in prevention and treatment of chemotherapy-induced oral mucositis, and the retrieval time was limited from their inception to April 2018. We assigned two independent investigators to perform a search, screen citations, extract information, and evaluate the risk of bias in all included trials. Subsequently, the RevMan 5.3 software was utilized to perform all statistical analyses. We included five eligible studies involving 352 patients. Meta-analysis based on limited data revealed that oral zinc sulfate failed to decrease the incidence of chemotherapy-induced oral mucositis (RR [relative risk] = 0.52, 95% CI [confidence interval] = 0.17–1.64) as well as relieve chemotherapy-induced oral mucositits grade (RR = 0.62, 95% CI = 0.11–3.56; RR = 0.70, 95% CI = 0.29–1.71). Moreover, qualitative analyses also suggested that oral zinc sulfate was not associated with reduced oral pain intensity, delayed onset of chemotherapy-induced oral mucositis, decreased adverse events, or improved quality of life compared with control regimes. Oral zinc sulfate may not provide clinical benefits in preventing or reducing incidence, severity, or pain intensity of chemotherapy-induced oral mucositis in cancer patients. However, more studies with large-scale and rigorous methods are warranted for the purpose of further investigating efficacy and safety of oral zinc sulfate for this pathologic condition due to the presence of limitations.

show abstract

“…The heterogeneity was qualitatively described by chi-square test, and quantitatively estimated by I 2 statistic which can estimate the proportion of the overall variation that is attributable to across study heterogeneity (37,38). When the number of included studies for individual outcome was less than 10, the funnel plot was not drawn (39).…”

Section: Discussionmentioning

confidence: 99%